BYD Made the Fortune Global 500 List for 2022
14.9.2022 16:06:00 EEST | Business Wire | Press release
On August 3rd, BYD made the Fortune Global 500 list for 2022, demonstrating its outstanding achievements in the market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220803005487/en/
BYD made the Fortune Global 500 list for 2022 (Photo: Business Wire)
Focusing on solving social problems, BYD remains dedicated to leveraging effective solutions for sustainable development. After years of progress, BYD has grown into a high-tech enterprise with its business scope covering automobiles, rail transit, new energy, and electronics. In pursuit of a greener world, BYD becomes a Fortune Global 500 enterprise that furnishes new energy overall solutions.
Amidst the backdrop of the recent rapid growth of the automobile industry, BYD leverages its strengths to usher in advanced technology, high quality products, and broader markets. Backed by its technologies, such as the Blade Battery, DM-i super hybrid technology, and the e-platform, BYD sold 730,093 passenger vehicles in 2021, including 593,745 new energy passenger vehicles, with a YoY increase of 231.6%. In China, BYD has cemented its status as the top seller of new energy passenger vehicles for nine consecutive years. In the first half of 2022, BYD sold 638,157 new energy passenger vehicles, up 324.8% YoY.
BYD has its sights set far beyond China. In the process of expanding the global footprint, BYD always embraces technological revolution and industrial transformation around the world. By incorporating global wisdom and sharing green technological innovations with consumers, BYD is on the path to be internationally competitive. Currently, BYD’s new energy vehicle footprint extends to over 400 cities and across 70 countries and regions on 6 continents. On July 21, BYD announced its official entry into the passenger vehicle market in Japan, marking a new chapter in the globalization of BYD passenger vehicles.
Since March 2022, BYD has ceased the production of cars powered only by internal combustion engines. Its shift to only producing battery electric vehicles and plug-in hybrid electric vehicles epitomizes the low-carbon transformation in the transportation industry.
At present, carbon emission reduction and new energy development are the global consensuses. As an international high-tech company, BYD is committed to providing new energy solutions worldwide. Exceeding its prestigious Global 500 status, BYD will continue to create technological innovations for a better life, promote sustainable development of society, and implement its Cool the Earth by 1℃ initiative.
About BYD
BYD (Build Your Dreams) is a multinational high-tech company devoted to leveraging technological innovations for a better life. BYD now has four industries including Auto, Electronics, New Energy, and Rail Transit. Since its foundation in 1995, the company quickly developed solid expertise in rechargeable batteries and has become a relentless advocate of sustainable development, successfully expanding its renewable energy solutions globally with operations in over 70 countries and regions. Its creation of a Zero Emissions Energy Ecosystem, comprising affordable solar power generation, reliable energy storage, and cutting-edge electrified transportation, has made it an industry leader in the energy and transportation sectors. BYD is a Warren Buffet-backed company and is listed both on the Hong Kong and Shenzhen Stock Exchanges. More information on the company can be found at http://www.byd.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005487/en/
Contact information
Asia-Pacific: Mia Gu, mia.gu@byd.com tel: +86-755-8988-8888-69666
Europe: Penny Peng,
PressEU@byd.com
tel: +31-102070888
North America: Frank Girardot, frank.girardot@byd.com tel: +1 213 245 6503
Latin America: Sofίa Mardones, sofia.mardones@byd.com tel: +56 9 9821 6851
Brazil: Adalberto Maluf, adalberto.maluf@byd.com tel: +19 3514 2554
Africa: Nikki Li,
li.namin@byd.com
tel: +86-18938862670
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom